Skip to main content
. 2021 Feb 15;15:1188. doi: 10.3332/ecancer.2021.1188

Table 4. Treatment plan of study participants.

Variable Frequency
Chemotherapy indication
Adjuvant
Neoadjuvant
Palliative

25 (22.1)
79 (69.9)
9 (8.0)
Chemotherapy (first-line regimen)
Anthracycline
Cyclophosphamide, Methotrexate, Fluorouracil
Taxane

111 (98.2)
1 (0.9)
1 (0.9)
Chemotherapy (second-line regimen) (n = 40)
Platinum
Taxane
Platinum and taxane

1 (2.4)
33 (80.6)
6 (14.6)